Literature DB >> 163608

The biochemical, clinical, and genetic features of type III hyperlipoproteinemia.

J Morganroth, R I Levy, D S Fredrickson.   

Abstract

The clinical and biochemical features of type III hyperlipoproteinemia are described in 49 patients from 23 to 70 years of age. An increase in very low-density lipoproteins (VLDL) of abnormal chemical composition was the basis for diagnosis. The untreated patients all had hypercholesterolemia and hyperglyceridemia, and, on the average, decreased concentrations of both low- and high-density lipoproteins. Seventy-four percent had xanthomas, and classic "xanthoma striata palmaris" was found in more than half. Twenty-seven percent had ischemic heart disease, detected earlier in men than in women. Twenty-seven percent had peripheral vascular disease (compared to 4% of subjects with type II hyperlipoproteinemia). Twenty-five of 35 subjects achieved normal lipid levels with dietary therapy alone. Analysis of 29 kindred showed hyperlipidemia in half of adult blood relatives; half of these had type III, the remainder usually had sample endogenous hyperglyceridemia (type IV). Only 2 of 55 children less than 20 years of age were affected, both with type IV.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 163608     DOI: 10.7326/0003-4819-82-2-158

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  29 in total

1.  Unraveling hyperlipidemia type III (dysbetalipoproteinemia), slowly.

Authors:  Juergen R Schaefer
Journal:  Eur J Hum Genet       Date:  2008-11-26       Impact factor: 4.246

2.  Evaluation of the classical methods for the diagnosis of type III hyperlipoproteinemia.

Authors:  J R Patsch; R L Jackson; A M Gotto
Journal:  Klin Wochenschr       Date:  1977-11-01

3.  Hyperlipidaemia, smoking and hypertension. The place of the hyperlipidaemias.

Authors:  J K Lloyd; R J West
Journal:  Postgrad Med J       Date:  1978-03       Impact factor: 2.401

4.  Postprandial plasma retinyl ester response is greater in older subjects compared with younger subjects. Evidence for delayed plasma clearance of intestinal lipoproteins.

Authors:  S D Krasinski; J S Cohn; E J Schaefer; R M Russell
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

5.  High receptor binding affinity of lipoproteins in atypical dysbetalipoproteinemia (type III hyperlipoproteinemia).

Authors:  D A Chappell
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

6.  Lipolytic surface remnants of triglyceride-rich lipoproteins are cytotoxic to macrophages but not in the presence of high density lipoprotein. A possible mechanism of atherogenesis?

Authors:  B H Chung; J P Segrest; K Smith; F M Griffin; C G Brouillette
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

7.  Apolipoprotein E synthesis in human kidney, adrenal gland, and liver.

Authors:  M L Blue; D L Williams; S Zucker; S A Khan; C B Blum
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

8.  Metabolism of apolipoproteins B-48 and B-100 of triglyceride-rich lipoproteins in patients with familial dysbetalipoproteinemia.

Authors:  A F Stalenhoef; M J Malloy; J P Kane; R J Havel
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

9.  Prevalence of the apolipoprotein E Arg145Cys dyslipidemia at-risk polymorphism in African-derived populations.

Authors:  Maen D Abou Ziki; Yael Strulovici-Barel; Neil R Hackett; Juan L Rodriguez-Flores; Jason G Mezey; Jacqueline Salit; Sharon Radisch; Charleen Hollmann; Lotfi Chouchane; Joel Malek; Mahmoud A Zirie; Amin Jayyuosi; Antonio M Gotto; Ronald G Crystal
Journal:  Am J Cardiol       Date:  2013-10-03       Impact factor: 2.778

Review 10.  Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline.

Authors:  Lars Berglund; John D Brunzell; Anne C Goldberg; Ira J Goldberg; Frank Sacks; Mohammad Hassan Murad; Anton F H Stalenhoef
Journal:  J Clin Endocrinol Metab       Date:  2012-09       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.